DEVELOPMENT PIPELINE

CureVac is developing cancer vaccines based on RNActiveŽ-derived molecules expressing protein antigens (mRNA-based vaccination).




NEWS

2009-11-02
CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer

CureVac beginnt Phase-IIa-Studie mit mRNA-Vakzin zur Behandlung von Prostatakrebs

DOWNLOADS

CureVac at a glance

Company Profile